Research Analysts Issue Forecasts for Exagen FY2025 Earnings

Exagen Inc. (NASDAQ:XGN) – Analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for Exagen in a research report issued on Thursday, May 15th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings of ($0.61) per share for the year, down from their prior estimate of ($0.59). Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share.

Exagen (NASDAQ:XGN) last issued its earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. The company had revenue of $15.50 million during the quarter, compared to analyst estimates of $14.55 million. During the same quarter last year, the firm earned ($0.19) EPS.

XGN has been the topic of several other research reports. BTIG Research reaffirmed a “buy” rating on shares of Exagen in a research note on Wednesday, May 7th. William Blair reissued an “outperform” rating on shares of Exagen in a research report on Wednesday, March 12th. Finally, Canaccord Genuity Group lifted their price target on shares of Exagen from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Tuesday, May 13th.

Exagen Trading Up 4.7%

NASDAQ:XGN opened at $6.01 on Monday. The stock has a fifty day simple moving average of $4.81 and a 200 day simple moving average of $4.24. The firm has a market capitalization of $128.01 million, a price-to-earnings ratio of -6.39 and a beta of 1.50. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. Exagen has a 1-year low of $1.71 and a 1-year high of $7.20.

Hedge Funds Weigh In On Exagen

Several hedge funds have recently added to or reduced their stakes in XGN. Corient Private Wealth LLC acquired a new position in shares of Exagen in the 4th quarter valued at $45,000. Virtu Financial LLC bought a new position in Exagen in the fourth quarter valued at approximately $46,000. Marshall Wace LLP bought a new position in shares of Exagen in the fourth quarter valued at $66,000. Northern Trust Corp increased its stake in shares of Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after purchasing an additional 2,630 shares during the last quarter. Finally, Huntleigh Advisors Inc. increased its position in Exagen by 16.8% during the first quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company’s stock worth $298,000 after buying an additional 11,939 shares during the last quarter. Institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).